Helicobacter pylori
- PMID: 1775918
- DOI: 10.3109/00365529109098219
Helicobacter pylori
Abstract
Helicobacter pylori is a unique pathogen and the leading cause of chronic gastric inflammation. For many individuals the organism is of low virulence, causing only mild inflammation and generating few, if any, dyspeptic symptoms. For those with more severe inflammation, H. pylori infection may be causal in the generation of dyspeptic symptoms. H. pylori infection appears to be the dominant factor in peptic ulcer disease. Events considered to be of importance are a disturbed gastrin homeostasis and the development of gastric metaplasia in the bulb. The most important argument in support of the dominant role of H. pylori in duodenal ulcer disease is the markedly reduced ulcer relapse after successful eradication. Eradication proves to be difficult, presumably because of the peculiar habitat of the organism. Currently the best pharmacologic approach is triple therapy, combining a bismuth salt, metronidazole, and amoxycillin or tetracycline.
Similar articles
-
Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.Eur J Gastroenterol Hepatol. 1994 Dec;6 Suppl 1:S103-7. Eur J Gastroenterol Hepatol. 1994. PMID: 7735924 Clinical Trial.
-
[Treatment of peptic ulcer and gastritis associated with Helicobacter pylori].Enferm Infecc Microbiol Clin. 1995 Aug-Sep;13(7):422-8. Enferm Infecc Microbiol Clin. 1995. PMID: 8519820 Review. Spanish. No abstract available.
-
Helicobacter pylori and gastroduodenal disease.Annu Rev Med. 1992;43:135-45. doi: 10.1146/annurev.me.43.020192.001031. Annu Rev Med. 1992. PMID: 1580578 Review.
-
Patients with endoscopic gastritis and/or duodenitis improve markedly following eradication of Helicobacter pylori, although less so than patients with ulcers.Scand J Gastroenterol. 2002 Dec;37(12):1386-94. doi: 10.1080/003655202762671251. Scand J Gastroenterol. 2002. PMID: 12523587 Clinical Trial.
-
Helicobacter pylori eradication--comparison of three drug regimens and symptomatic assessment in duodenitis and antral gastritis.Int J Clin Pract. 1997 Jun;51(4):214-6. Int J Clin Pract. 1997. PMID: 9287260 Clinical Trial.
Cited by
-
Ranitidine: a pharmacoeconomic evaluation of its use in acid-related disorders.Pharmacoeconomics. 1994 Jul;6(1):57-89. doi: 10.2165/00019053-199406010-00007. Pharmacoeconomics. 1994. PMID: 10147354 Review.
-
Helicobacter pylori infection density and gastric inflammation in duodenal ulcer and non-ulcer subjects.Gut. 1995 Sep;37(3):319-24. doi: 10.1136/gut.37.3.319. Gut. 1995. PMID: 7590424 Free PMC article.
-
Inhibition of Helicobacter pylori adherence by a peptide derived from neuraminyl lactose binding adhesin.Mol Cell Biochem. 2001 Dec;228(1-2):83-9. doi: 10.1023/a:1013314604403. Mol Cell Biochem. 2001. PMID: 11855744
-
Recurrence of Helicobacter pylori infection after successful eradication: nature and possible causes.Dig Dis Sci. 1997 Sep;42(9):1821-34. doi: 10.1023/a:1018827322470. Dig Dis Sci. 1997. PMID: 9331143 Review.
-
Progress with proton pump inhibition.Yale J Biol Med. 1992 Nov-Dec;65(6):649-57;discussion 689-92. Yale J Biol Med. 1992. PMID: 1341069 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical